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Previous studies report larger myocardial infarcts 
and increrued in-hospital mortality rates in patients 
with inferior wall acute myocardlal infarction (AMI) 
and complete atrioventricular block (AV), but the 
clinical impliitionr of these complications in pa- 
tients treated with &don therapy have not 
been addressed. The clinical course of 373 pa- 
tients- SO (13%) of whom developed complete 
AV block- admitted with inferior wall AMI and 
given thrombolytic therapy within 6 hours of symp- 
tom onset was studied. Acute patency rates of the 
infarct artery after thrombolytic therapy were simi- 
lar in patients with or without AV block. Ventricu- 
lar function mearwed at baseline and before dis- 
charge in patients with complete AV block showed 
a decrement in medlan ejection fraction (-3.5 vs 
-0.496, p = 0.03) and in median regional wall mo- 
tion (-0.14 vs +0.24 standard deviations/chord, p 
= 0.05). The reocclusion rate was higher in pa- 
tients with complete AV block (26 vs 16%, p = 
0.03). Patients with complete AV Mock had more 
episodes of ventricular fibrillation or tachycardia 
(36 vs 1496, p <O.OOl), sustained hypotension (36 
VI lo%, p <O.OOl), pulmonary edema (12 vs 4%, 
From the Division of Cardiology, Department of Medicine, Duke Uni- 
versity, Durham, North Carolina; Division of Cardiology, Department 
of Internal Medicine, University of Michigan, Ann Arbor, Michigan; 
The Riverside Methodist Hospital, Columbus, Ohio; and the Christ 
Hospital, Cincinnati, Ohio. This study was presented in part at the 
American College of Cardiology, 38th Scientific Session, Anaheim, 
California, and supported in part by research grants from Genentech 
Inc., San Francisco, California, Abbott Laboratories, Chicago, Illinois 
and by Research Grants HS-05635 and HS-04873 from the Agency for 
Health Care Policy and Research, Rockville, Maryland, by Research 
Grants HL-17670 and HL-36587 from the National Heart, Lung, and 
Blood Institute, Bethesda, Maryland, and by grants from the Robert 
Wood Johnson Foundation, Princeton, New Jersey. Manuscript re- 
ceived April 16, 1990, revised manuscript received and accepted Sep 
tember 26,199O. 
Address for reprints: Robert M. Califf, MD, Duke University Med- 
ical Center, Division of Cardiology, P.O. Box 3 1123, Durham, North 
Carolina 27710. 
*See Appendix. 
p = 0.02) and a higher in-hospital mortalii rate 
(20 VI 4%, p <O.OOl), although the mortality rate 
after hospital discharge was idsntlcal(2%) in the 2 
groups. Multlvariable logistic regression analysis 
revealed that complete AV blodc was a strong inde- 
pendent predictor of in-hospital mortalRy (p = 
0.0006). Thus, despite hdtial successfuireperfu- 
sion, patients with inferior wall AMI and complete 
AV block have higher rates of in-hospital complica- 
tions and mortality. 
(Am J Cardid 1661;67:225-230) 
I nferior wall acute myocardial infarction (AMI) is of- ten complicated by atrioventricular (AV) block. Be- fore the widespread use of thrombolytic therapy, 
complete AV block occurred in 8 to 13% of such pa- 
tients during the hospital course.1-3 Several investiga- 
tors report that larger infarctions are associated with 
AV block and that a high incidence of in-hospital com- 
plications and an increased short-term mortality rate 
occur among patients with complete AV block.1-3 The 
long-term outcome of hospital survivors, however, seems 
unaffected by the occurrence of complete AV block 
during hospitalization. 1,4 One previous study suggested 
that complete AV block in patients with an inferior wall 
myocardial infarction is associated with coexistent mul- 
tivessel disease.5 The aforementioned studies were all 
conducted in the prethrombolytic era. The clinical im- 
plications of complete AV block in patients treated with 
reperfusion therapy have not been addressed. Whether 
the Occurrence of complete heart block is an indepen- 
dent risk factor for mortality has not been evaluated, 
because acute coronary anatomic and left ventricular 
function findings have not been available. We therefore 
undertook the present study to describe the clinical 
course and prognostic significance of complete AV 
block complicating inferior wall AM1 in patients treat- 
ed with reperfusion therapies. 
METHODS 
Patient population: The study population was culled 
from 8 10 consecutive patients who participated in 4 
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clinical trials conducted by the Thrombolysis and Angi- 
oplasty in Myocardial Infarction (TAMI) study group, 
which studied different thrombolytic therapeutic strate- 
gies. Briefly, patients admitted within 6 hours of symp- 
tom onset with an AM1 were enrolled if they met the 
following criteria: electrocardiographic evidence of epi- 
cardial injury, defined as 20.1 mV ST-segment eleva- 
tion in 12 contiguous leads; absence of previous Q-wave 
infarction in the distribution of the acute ischemic re- 
gion; and chest pain 230 minutes’ duration unrespon- 
sive to standard sublingual nitroglycerin therapy. Pa- 
tients were ineligible for the study if they had a history 
of a significant bleeding diathesis or a known bleeding 
disorder, a history of gastrointestinal or genitourinary 
bleeding within the preceding 4 weeks, a stroke in the 
past 6 months, major surgery in the preceding 2 weeks, 
uncontrolled hypertension (diastolic blood pressure re- 
peatedly >l 10 mm Hg), other serious advanced illness, 
cardiogenic shock (systolic blood pressure <85 mm Hg 
unresponsive to volume expanders), prolonged cardio- 
pulmonary resuscitation in the preceding 2 weeks, se- 
vere trauma within the past 6 months, psychological or 
physical inability to participate, or if they were women 
of child-bearing potential. 
Patients underwent acute cardiac catheterization 
and the cineangiograms were recorded for later, inde- 
pendent analysis by a control angiographic core labora- 
tory. The culprit infarct artery was determined to be the 
left anterior descending artery in 307 patients, the left 
circumflex artery in 104 patients and the right coronary 
artery in 373 patients. The remaining 26 patients had 
occlusion of the left main stem, or coronary bypass 
grafts, or the infarct artery could not be determined. 
Complete AV block occurred in 62 patients (8%). This 
complication was almost entirely limited to patients 
with right coronary artery-related infarction (n = 50) 
and rarely occurred with left anterior descending (n = 
6) or left circumflex artery (n = 6) infarction. The fo- 
cus of this study was therefore confined to the 373 pa- 
tients with inferior wall AM1 because of occlusion of 
the right coronary artery. Written informed consent was 
obtained from all patients before entry into studies. En- 
rollment of patients into the 4 studies began December 
10, 1985, and ended March 24, 1988. 
Data collection and definitions: Data pertaining to 
baseline characteristics, treatment and outcome were 
collected by research nurses and audited by a second 
nurse before analysis. Specific characteristics pertaining 
to complete heart block (duration, associated features) 
were collected on an ancillary data form by research 
nurses and fellows. Complete heart block was defined 
by standard clinical criteria: complete dissociation of 
the atria1 and ventricular rates, with the atria1 rate 
greater than the ventricular rate. 
In most cases cardiac rhythm strips were available, 
but, in some instances, clinical observation of the cardi- 
ac monitor led to the diagnosis even though a hard copy 
was not available. The definitions of clinical variables 
have been published previously.6-g 
Follow-up information was obtained by telephone or 
self-administered questionnaires given to patients or 
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nearest relatives. The last follow-up contact occurred at 
a median of 22 months after hospital discharge; follow- 
up was 97% complete. 
Thrombolytic regimen: Intravenous thrombolytic 
therapy was given to all patients. Of the 386 patients 
enrolled in the TAMI- trial, the first 178 patients re- 
ceived recombinant tissue-type plasminogen activator at 
a dose of 60 mg/hour during the first hour, 20 mg/hour 
during the second and third hours and 10 mg/hour in 
the last 5 hours. The remaining 208 patients received 1 
mg/kg in the first hour (to a maximum dose of 90 mg), 
with the remainder of the dose given continuously as a 
5-hour infusion for a total dose of 150 mg. All patients 
had 10% of the first hourly dose administered as a bolus 
injection over 6 minutes.6 Of the 147 patients in the 
TAMI- study, 34 patients received 25 mg of single- 
chain recombinant tissue-type plasminogen activator in 
addition to urokinase (0.5 to 1.0 million units of uroki- 
nase). The remaining 112 patients received 1 mg/kg of 
tissue plasminogen activator in addition to urokinase in 
varying doses (0.5, 1.5 and 2.0 million units, respective- 
ly).’ The 175 patients in the TAMI- study received 1.5 
mg/kg recombinant tissue-type plasminogen activator. 
Half the patients received a bolus dose of heparin on 
hospital admission and all received a full dose of hepa- 
rin 90 minutes after infusion of recombinant tissue-type 
plasminogen activator.* The 102 patients in the uroki- 
nase study received 3 million units over 45 to 60 min- 
utesg 
Angiographii studies: All patients underwent diag- 
nostic cardiac catheterization with angiographic visual- 
ization of all 3 major coronary arteries and a left ven- 
triculogram 190 minutes after the administration of 
thrombolytic therapy. All patients received 5,000 units 
of intravenous heparin subsequent to arterial access. 
Quantitative estimation of the flow in the infarct-relat- 
ed coronary artery was performed by Thrombolysis in 
Myocardial Infarction (TIMI) classification criteria.lO 
Arteries with TIM1 flow grade 0 or 1 were considered 
occluded and arteries with flow grade 2 or 3 were con- 
sidered patent. Reocclusion was defined in patients not 
occluded upon leaving the diagnostic catheterization as 
recurrent total occlusion of the infarct-related artery. 
Lesion location was defined as proximal or distal in re- 
lation to the first right ventricular branch of the right 
coronary artery. Percutaneous transluminal coronary 
angioplasty was performed when anatomically feasible 
in all patients with a TIM1 flow grade of 0 to 1. Pa- 
tients with TIM1 flow grade 2 or 3 underwent percu- 
taneous transluminal coronary angioplasty in accor- 
dance with the different protocols (by randomization in 
TAMI- 1, and if clinical evidence of ongoing ischemia 
persisted in TAMI-2, TAMI- and the urokinase 
study). When acute percutaneous transluminal coro- 
nary angioplasty was performed, an additional 5,000 
units of heparin were given. In patients with angio- 
graphically visible filling defects suggesting the presence 
of residual thrombus, 30 mg of intracoronary recombi- 
nant tissue-type plasminogen activator or 300,000 units 
of intracoronary urokinase were administered. An effort 
was made to perform a repeat cardiac catheterization in 
TABLE I Baseline Characteristics of 373 Patients with Right 
Coronary Artery Infarct Events 
Complete AVB No Complete AVB 
(n = 50) (n = 323) 
Age (median, 60 (53-66) 57 (49-64) 
interquartile range) 
Male gender (%) 37 (74) 257 (80) 
History of smoking (%) 31(62) 217 (67) 
Diabetes (%) 10 (20) 41(13) 
Family history of CAD (%) 19 (38) 153 (47) 
Hypertension (%) 19 (38) 136 (42) 
Hyperlipidemia (%) 4 (8) 43 (13) 
History of angina (%) 19 (38) 151(48) 
Time to Rx (median in 159(120-197) 170(122-214) 
minutes, interquartile 
range) 
Multivessel disease* (%) 15 (30) 133 (42) 
* >_75% stenow of >2 major epicardial coronary arteries. 
AVB = atrloventrlcular block; CAD = coronary artery dn?ase; Rx = thrombolytlc 
therapy 
all patients as close as possible to the seventh day after 
hospital admission. Global left ventricular ejection frac- 
tion was determined by the area-length method” and 
regional wall motion of the infarct zone by the center- 
line chord method.12 Both the acute and predischarge 
angiographic studies were analyzed at the angiographic 
core laboratory by independent observers. 
Hospital care: All patients were admitted to the cor- 
onary care unit, where cardiac rhythm was routinely 
monitored for 24 hours. Medical therapy included intra- 
venous lidocaine for 24 hours, 1 enteric-coated aspirin 
tablet (325 mg) per day and diltiazem (60 mg) every 6 
hours for 7 days. Heparin was administered by intrave- 
nous infusion up to 7 days to a level of activated partial 
thromboplastin time 1.5 to 2.5 times greater than con- 
trol values. Beta blockers were only administered when 
clinically indicated (supraventricular tachycardia, hy- 
pertension or angina pectoris). All additional revascu- 
larization procedures, including percutaneous translu- 
minal coronary angioplasty or coronary artery bypass 
grafting, were performed as clinically indicated at the 
discretion of the attending physician. Temporary trans- 
cutaneousI or transvenous pacemakers were used at the 
discretion of the treating physician. 
Data analysis: Unless otherwise indicated, all con- 
tinuous variables describing patient characteristics were 
described in terms of the median and interquartile 
range. Discrete variables were described by frequencies 
and percentages. Group differences in proportions were 
examined with the chi-square test. Patient groups were 
compared with respect to continuous variables by the 2- 
sample Wilcoxon rank-sum test. Two-sided p values 
<0.05 were considered statistically significant. Multiple 
logistic regression analysis was performed to determine 
the importance of complete AV block as a predictor of 
in-hospital mortality relative to other prognostic clinical 
and angiographic variables. 
RESULTS 
Complete AV block was observed in 50 of the 373 
patients (13%) with an AM1 related to the right coro- 
r TABLE II Clinical Characteristics of Complete 
Atrioventricular Block in 50 Patients Treated with Reperfusion 
Therapy 
Duration rn hours 
(median, interquartile range) 
















PTCA = percutaneous translumlnal coronary ang~oplas~; VT/VF = ventricular 
tachycarde and ventricular fibrlllatlan: other abbreviations as I” Table I I 
nary artery. No substantial differences in clinical base- 
line characteristics were found between the 2 groups 
(Table I), although the patients with complete AV 
block did appear to have a slightly lower percentage of 
multivessel disease and a lower percentage of a history 
of angina pectoris. 
Figure 1 shows the time from onset of chest pain to 
the first recorded episode of complete AV block. In 54% 
of patients, complete AV block was present on admis- 
sion and developed in all except 2 patients within 72 
hours after symptom onset. Immediate treatment of 
complete AV block included temporary pacemakers in 
60% of the patients. In 8%, the pacemaker was inserted 
prophylactically, before the development of complete 
AV block. Atropine was administered to 82% of the pa- 
tients with complete AV block. The block was transient 
in all but 1 patient, who required insertion of a perma- 
nent pacemaker after aortocoronary bypass surgery. 
Duration of complete AV block was I1 hour in 25% of 
the patients and <12 hours in 75% (median duration 
2.5 hours). Complete AV block could be associated with 
chemical reperfusion, angioplasty or reocclusion in 38% 
of patients (Table II). Immediate complications associ- 
ated with the development of complete AV block oc- 
curred often and included hypotension, ventricular 










Admission 16 524 172 
Time (hours) 
FlGURE 1. Gumdative perwdage of patients developing 
complate atwiov~ block~6,24and72hoursaRerem 
set ol myocardial infarction. 
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TABLE IV Clinical Outcomes 
VT/VF(%) (Unrelated to 
bradycardia) 
Sustained hypotension (%) 
Congestive heart failure (%) 
Pulmonary edema (%) 
In-hospital mortality (%) 
Long-term mortality (%) 
(22-month follow-up) 
Complete No Complete 
AVB AVB p Value 
(n = 50) (n = 323) 
18 (36) 46 (14) <O.ool 
18 (36) 33(10) <O.ool 
13 (26) 17(5) <O.ool 
6G’) 13 (4) 0.02 
10 (20) 12(4) <0.001 
l(2) 6 (2) NS 
NS = not significant; other abbreviations as in Tables I and II 
TABLE III Infarct Artery Status I 
Complete AVB 
(n = 50) 
No Complete AVB 
(n = 323) 
Proximal lesion (%) 
Drstal lesion (%) 





















* First diagnostic an@gram. 
7 Final patency = infarct artery patency status after acute pharmacologic and 
mechanical Interventions. 
Abbreviations as I” Tables I and Il. 
The infarct artery status is summarized in Table III. 
There was no difference between the patency of the in- 
farct artery after thrombolytic therapy and the patency 
after acute catheterization: 90% in patients with and 
91% in those without complete AV block. However, pa- 
tency before hospital discharge was 11% lower in the 
patients with complete AV block because of a higher 
reocclusion rate (29 vs 16%, p = 0.03). 
Global and regional left ventricular function data 
are shown in Figures 2 and 3. At acute angiography, the 
mean ejection fraction in the group with complete AV 
block was 56%, compared with 55% in the group with- 
out. At follow-up angiography, there was no change in 
the ejection fraction in patients without complete AV 
block, but there was a 3.5% decrease in the group with 
complete AV block (p = 0.03). The mean acute infarct 
zone wall motion was -2.49 standard deviations/chord 
with complete AV block and -2.39 standard devi- 
ations/chord without. Before discharge, acute infarct 
zone wall motion improved in the group without com- 
plete AV block and decreased further in the group with 
complete AV block. The trend toward more functional 
recovery of the infarct zone among patients without 
complete AV block was of borderline statistical signifi- 
cance (p = 0.05). 
The clinical outcomes of the 2 groups are listed in 
Table IV. The in-hospital course was more complicated 
60 I I 
-10 ’ I 1 
Acute 7-Day Change 
I 
1 
in the patients who developed complete AV block. Ven- 
tricular fibrillation or tachycardia occurred in 36 vs 
14% and sustained hypotension in 36 vs lo%, respective- 
ly. Ten of the 50 patients with complete AV block 
(20%) died in-hospital versus only 12 of 323 without 
(4%) (p <O.OOl). The long-term mortality rates of the 
hospital survivors after a median follow-up of 22 
months were identical (2%) in the 2 groups. 
The independent prognostic value of complete AV 
block was examined by logistic regression analysis. 
When age, acute left ventricular ejection fraction, num- 
ber of diseased vessels and TIM1 grade flow were en- 
tered into a multivariable logistic regression model, 
complete AV block contributed independent prognos- 
tic information concerning in-hospital mortality (chi- 
square = 11.6, p = 0.0006). 
DISCUSSION 
The major finding of this study was that the inci- 
dence of complete AV block in patients with AM1 
treated with thrombolytic therapy is similar to the inci- 
dence reported before the thrombolytic era.1-3,5J4 Fur- 
thermore, when compared with historical populations, 
the mortality rate in the group of patients who devel- 
oped complete AV block was not lower, despite aggres- 
sive reperfusion attempts, usually with success in this 
population.1-3J4J5 Our findings of a somewhat more de- 
pressed regional and global left ventricular function are 
I 
1 








Acute 7-Day Change 




AVB = atrlovonbidar blocIt. 
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FIGURE 3. Regional wall motbn of the hfarct zone as deter- 
minedbythecentedinechordmethodforthe2gmups.Vahes 
repwentmaansofpabwl~andprscGscbergestudiss.SD 
= stmdard dsviationr; other abtmwiation as in Figure 2. 
in agreement with those of previous studies that de- 
scribe larger infarcts and more depressed left ventricu- 
lar function in the patients who developed complete AV 
block compared with those who did not.1m3J5 
A recent study by Nicod et all involving patients 
who did not undergo thrombolytic intervention found 
that complete AV block was an independent factor for 
in-hospital prognosis when correcting for other noninva- 
sive factors known to be important for prognosis. This 
finding was confirmed in the present study, where com- 
plete AV block was a strong predictor of in-hospital 
mortality, even after considering variables obtained via 
cardiac catheterization, including acute left ventricular 
ejection fraction, number of diseased vessels and TIM1 
grade flow after thrombolytic therapy. Long-term prog- 
nosis of hospital survivors was good in the present study 
and unaffected by the development of complete AV 
block in the hospital. Other studies conducted in the 
prethrombolytic era have reported similar results.‘J6 
In the present as well as in previous studies, com- 
plete AV block was transient in almost all patients.‘,3,‘7 
According to Hackel et al,l8 the transient nature of 
complete AV block in these patients is probably due to 
the relative resistance of the conduction system to isch- 
emia. These investigators summarized several mecha- 
nisms that, alone or in combination, could cause tran- 
sient complete AV block in these patients, all of which 
could be altered by myocardial reperfusion. Reperfusion 
could diminish the severity of local metabolic changes 
and the total duration of ischemia of the AV node. Con- 
versely, restoration of anterograde blood flow to previ- 
ously ischemic myocardium might both facilitate leuko- 
cyte migration to the infarcted area and stimulate vagal 
nerve endings in the inferoposterior aspects of the left 
ventricle.r8 Based on the findings in the present study, it 
appears that the major effect of reperfusion on the nat- 
ural history of complete AV block is to minimize its 
duration, possibly because the ischemic burden on the 
AV node is relieved. Indeed, the 25hour median dura- 
tion of the 3’ AV block in this study is the shortest ever 
reported in a large series of patients. 
In the present study, complete AV block was associ- 
ated with an active component of reperfusion therapy 
(reperfusion, angioplasty or reocclusion) in 38% of pa- 
tients, raising the possibility that reperfusion could itself 
provoke the AV block. Clinicians should thus be pre- 
pared for this complication to arise when other clinical 
markers of reperfusion occur, when angioplasty is cho- 
sen as an adjunctive therapy or when the patient devel- 
ops clinical signs of reocclusion. 
A recent study hypothesized that patients who devel- 
op acute AV block have a high incidence of multivessel 
disease, particularly co-existing obstruction of the left 
anterior descending artery.5 That study comprised only 
51 patients, and the 32 patients with 175% stenosis of 
the left anterior descending artery had a 31% incidence 
of AV block versus a 1% incidence among the patients 
without significant disease of that artery. Our findings 
are in agreement with another recent large study of 749 
patients, which failed to detect such a relation.’ 
Study limitations: The ideal study design for an- 
swering the question of the impact of 3’ AV block on 
patient outcome after thrombolytic therapy would in- 
clude a control group not undergoing any clinical at- 
tempt at myocardial reperfusion. However, such a study 
would be almost impossible to conduct in the present 
era, and our comparisons are therefore limited to lind- 
ings of previous studies conducted before the wide- 
spread use of reperfusion therapies. The clinical defini- 
tion of AV block used in this study is not as complete as 
what could be achieved by continuous Holter monitor- 
ing of a large population. Transient episodes of com- 
plete AV block could have been missed, or, in some 
cases, AV dissociation could have been erroneously la- 
beled as heart block. Nevertheless, these findings are 
representative of current practice in institutions with a 
full-time cardiology staff observing patients with AMIs. 
Also, the critical question of right ventricular involve- 
ment in patients with complete AV block cannot be an- 
swered by the present study, because right ventricular 
infarction was not routinely assessed in this popula- 
tion. A previous study has found that the right ventricle 
is involved in the majority of patients with inferior wall 
myocardial infarction who develop advanced AV 
block.15 
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